Business Context and Reporting Period
This Form 6-K filing by Can-Fite Biopharma Ltd. covers the month of September 2019, specifically dated September 11, 2019. The report addresses urgent legal proceedings initiated by Capital Point Ltd. regarding a collaboration agreement with Univo Pharmaceuticals Ltd.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on legal and corporate governance matters rather than financial performance.
Material Changes and Legal Proceedings
- Legal Action: Capital Point Ltd. filed a motion on September 11, 2019, seeking a preliminary and temporary injunction to prevent Can-Fite from executing transactions under its collaboration agreement with Univo, specifically the issuance of ordinary shares.
- Court Ruling: The District Court of Tel Aviv granted a temporary injunction on an ex parte basis on September 11, 2019, pending a hearing scheduled for September 18, 2019.
- Transaction Status: The collaboration transaction was consummated on September 10, 2019, and the ordinary shares were issued to Univo prior to the filing of Capital Point's motion.
Outlook, Risks, and Management Commentary
The primary risk identified is the potential disruption of the collaboration agreement with Univo due to the ongoing litigation and the temporary injunction. Management has not provided financial guidance or outlook in this specific filing. The situation remains contingent on the outcome of the court hearing scheduled for September 18, 2019.
Investor Verification Checklist
- Verify the outcome of the court hearing scheduled for September 18, 2019, regarding the temporary injunction.
- Confirm whether the issuance of shares to Univo remains valid despite the injunction.
- Monitor for further updates on the legal proceedings initiated by Capital Point Ltd.